88 related articles for article (PubMed ID: 3158861)
1. [Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Wander HE; Teichmann AT; Cremer P; Wieland H; Kruse B; Nagel GA; Kuhn W; Seidel D
Onkologie; 1985 Apr; 8(2):88-92. PubMed ID: 3158861
[TBL] [Abstract][Full Text] [Related]
2. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
[TBL] [Abstract][Full Text] [Related]
3. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA
Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938
[No Abstract] [Full Text] [Related]
4. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
5. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
6. High-dose depot-medroxyprogesterone acetate (DMPA) - effects on lipid and lipoprotein metabolism.
Crona N; Enk L; Samsioe G; Silfverstolpe G; Skryten A
Eur J Obstet Gynecol Reprod Biol; 1983 Oct; 16(2):97-105. PubMed ID: 6227506
[TBL] [Abstract][Full Text] [Related]
7. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal control of disseminated breast cancer].
Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
Sov Med; 1990; (6):94-7. PubMed ID: 2144368
[No Abstract] [Full Text] [Related]
9. Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.
Hultborn R; Johansson-Terje I; Bergh J; Glas U; Hallsten L; Hatschek T; Holmberg E; Ideström K; Norberg B; Ranstam J; Söderberg M; Wallgren UB
Acta Oncol; 1996; 35 Suppl 5():75. PubMed ID: 9142972
[No Abstract] [Full Text] [Related]
10. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
11. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.
Petru E; Schmähl D
Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170
[TBL] [Abstract][Full Text] [Related]
12. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC
Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
[TBL] [Abstract][Full Text] [Related]
13. Management of breast cancer with bone metastases.
Clavel M
Bone; 1991; 12 Suppl 1():S11-2. PubMed ID: 1720011
[No Abstract] [Full Text] [Related]
14. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone.
Alberto P; Mermillod B; Kaplan E; Goldhirsch A; Obrecht JP; Jungi F; Martz G; Barrelet L; Cavalli F
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):423-8. PubMed ID: 3891359
[TBL] [Abstract][Full Text] [Related]
15. [Value of hormone therapy in metastasizing breast cancer].
Samonigg H
Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
[TBL] [Abstract][Full Text] [Related]
16. Medroxyprogesterone acetate and lipid metabolic changes.
Teichmann AT; Wander HE; Cremer P; Wieland H; Kuhn W; Nagel GA; Seidel D
Arzneimittelforschung; 1987 May; 37(5):573-7. PubMed ID: 2956958
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.
Canney PA; Priestman TJ; Griffiths T; Latief TN; Mould JJ; Spooner D
J Natl Cancer Inst; 1988 Sep; 80(14):1147-51. PubMed ID: 2970555
[TBL] [Abstract][Full Text] [Related]
18. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
Wander HE; Blossey HC; Nagel GA
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1371-4. PubMed ID: 3830219
[TBL] [Abstract][Full Text] [Related]
19. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
20. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men.
Rhoads GG; Gulbrandsen CL; Kagan A
N Engl J Med; 1976 Feb; 294(6):293-8. PubMed ID: 173994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]